Shares of Exelixis, Inc. EXEL have surged 50% in a year against the industry’s decline of 16.1%. The stock has also ...

Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Oropharyngeal Cancer. According to GlobalData, Phase III drugs for Oropharyngeal Cancer have a 17% phase ...

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib ...

Enrollment has been completed in the late-stage STELLAR-303 study evaluating zanzalintinib, in combination with Tecentriq, compared with regorafenib in patients with metastatic refractory ...

Another promising candidate in Exelixis’ pipeline is zanzalintinib, a next-generation oral. Enrollment has been completed in the late-stage STELLAR-303 study evaluating zanzalintinib ...

The focus now turns to Exelixis's drug zanzalintinib, a multi-kinase inhibitor currently undergoing trials for colorectal cancer (CRC). While the probability of success for zanzalintinib in CRC ...

Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Hypopharyngeal Cancer.